A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil

Sexually Transmitted Infections

Volumn 79, Issue 6, 2003, Pages 448-452

  Lambert, J S ^a,b   Nogueira, S A ^c   Abreu, T ^c   Machado, E S ^c   Costa, T P ^c   Bondarovsky, M ^c   Andrade, M ^c   Holpern, M ^d   Barbosa, R ^d   Perez, M ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d Hospital Raphael de Paula Souza   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOVIR; CD4 ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BONE MARROW TOXICITY; BRAZIL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIXED DRUG DOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LEUKOCYTE COUNT; NEUTROPENIA; NEWBORN; NONHUMAN; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD;

EID: 9144263015     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.79.6.448     Document Type: Article

References (23)

1. Conner EM, Sperling R, Gelber R, et al. Reduction of maternal-infant transmission of HIV-1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Grubert TA, Wintergeerst U, Lota-Friedreich R, et al. Long-term antiretroviral combination therapy including lamivudine in HIV-1 infected women during pregnancy. AIDS 1999;13:1430-1.
3. Saba J. The results of the PETRA intervention trial to prevent perinatal transmission in sub-Saharan Africa. From Sixth Conference on Retroviruses and Opportunistic Infections; 31 January-4 February 1999; Chicago, IL, Abstract S6.
4. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998;12:F241-7.
5. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128.
6. Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy: a focus on safety. Drug Saf 2001;24:683-702.
7. Mofenson LM. Perinatal exposure to zidovudine: benefits and risks N Engl J Med 2000;343:803-5.
8. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV Transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. J Infect Dis 1999;179:567-75.
9. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, 5 December 2001.
10. Dhalia C, Barreira D, Castilho EA. A AIDS no Brasil: situacao atual e tendencias. Brasil: Ministerio de Saude, Boletim Epidemiologico-AIDS 2000;XIII:3-13.
11. Lyall EG, Blott M, de Ruiter A, et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. British HIV Association. HIV Med 2001;2:314-34.
12. Edwards SG, Larbalestier N, Hay P, et al. Experience of nevirapine use in a London cohort of HIV-infected pregnant women. HIV Med 2001;2:89-91.
13. Mirochnick M, Siminski S, Fenton T, et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001;20:803-5.
14. Guay A, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;254:795-802.
15. Masquelier B, Chaix ML, Burgand M, et al. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr 2001;27:99-104.
16. Johnson VA, Petropoulos CJ, Woods CR, et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1 infected infant. J Infect Dis 2001;183:1688-93.
17. Kamkamidze G, Sullivan T, Charbonneau T. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants. J Clin Virol 2001;22:143-8.
18. Clarke JR, Braganza R, Mirza A, et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999;59:364-8.
19. Moodley J, Moodley K, Coovadia PH, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in HIV-1 infected pregnant women and their offspring. J Infect Dis 1998;178:1327-33.
20. Mandelbrot L, Peytavin G, Firtion G, et al. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 2001;184:153-8.
21. Silverman NS, Watts DH, Hitti J, et al. Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. Infect Dis Obstet Gynecol 1998;6:237-43.
22. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285:2083-93.
23. Chaisilwattana P, Chokephaibulkit K, Chalermchockcharoenkit A, et al. Short course therapy with zidovudine plus lamivudine for prevention of mother to child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 2002;35:1405-13.